A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Sep 29, 2006
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more.
- Exclusion Criteria:
- • History of no-response to timolol
- • History of trabeculectomy
- • History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hiroshima, , Japan
Kanazawa, Ishikawa, Japan
Gifu, , Japan
Miyakonojo, Miyazaki, Japan
Ichinomiya, Aichi, Japan
Ichinomiya, Aichi, Japan
Nagoya, Aichi, Japan
Nagoya, Aichi, Japan
Nagoya, Aichi, Japan
Narashino, Chiba, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Koube, Hyogo, Japan
Fujisawa, Kanagawa, Japan
Kamakura, Kanagawa, Japan
Sagamihara, Kanagawa, Japan
Yokohama, Kanagawa, Japan
Sapporo, Kokkaido, Japan
Uji, Kyoto, Japan
Kumagaya, Saitama, Japan
Tokorozawa, Saitama, Japan
Fuji, Shizuoka, Japan
Fuji, Shizuoka, Japan
Mishima, Shizuoka, Japan
Susono, Shizuoka, Japan
Bunkyo Ku, Tokyo, Japan
Chiyoda Ku, Tokyo, Japan
Chiyoda, Tokyo, Japan
Hachioji, Tokyo, Japan
Hamura, Tokyo, Japan
Katsushika Ku, Tokyo, Japan
Kiyose, Tokyo, Japan
Koto Ku, Tokyo, Japan
Meguro Ku, Tokyo, Japan
Meguro, Tokyo, Japan
Musashino, Tokyo, Japan
Musashino, Tokyo, Japan
Ota Ku, Tokyo, Japan
Setagaya, Tokyo, Japan
Shinjuku, Tokyo, Japan
Tachikawa, Tokyo, Japan
Taito Ku, Tokyo, Japan
Fujuoka, , Japan
Fukuoka, , Japan
Fukuoka, , Japan
Fukuoka, , Japan
Niigata, , Japan
Osaka, , Japan
Osaka, , Japan
Osaka, , Japan
Shizuoka, , Japan
Sugita, , Japan
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials